Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-55208
Oncol Lett 2018 Sep 01;163:2823-2832. doi: 10.3892/ol.2018.9016.
Show Gene links Show Anatomy links

Overexpression of TPX2 is associated with progression and prognosis of prostate cancer.

Zou J , Huang RY , Jiang FN , Chen DX , Wang C , Han ZD , Liang YX , Zhong WD .


Abstract
Targeting protein for Xenopus kinesin-like protein 2 (TPX2) activates Aurora kinase A during mitosis and targets its activity to the mitotic spindle, serving an important role in mitosis. It has been associated with different types of cancer and is considered to promote tumor growth. The aim of the present study was to explore the role of TPX2 in diagnosing prostate cancer (PCa). It was identified that TPX2 expression in PCa tissues was increased compared with benign prostate tissues. Microarray analysis demonstrated that TPX2 was positively associated with the Gleason score, tumor-node-metastasis (TNM) stage, clinicopathological stage, metastasis, overall survival and biochemical relapse-free survival. In vitro studies revealed that the high expression of TPX2 in PCa cells improved proliferative, invasive and migratory abilities, and repressed apoptosis of the PCa cells, without affecting tolerance to docetaxel. The results suggested that TPX2 serves as a tumorigenesis-promoting gene in PCa, and a potential therapeutic target for patients with PCa.

PubMed ID: 30127868
PMC ID: PMC6096215
Article link: Oncol Lett


Species referenced: Xenopus
Genes referenced: bcr btg2 tpx2

Disease Ontology terms: prostate cancer
OMIMs: PROSTATE CANCER

Article Images: [+] show captions
References [+] :
Antonarakis, Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. 2011, Pubmed